Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Douglas Tremblay, MD
Based on three randomized-controlled trials, the JAK inhibitor momelotinib has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly in patients with myelofibrosis. But what do we know about its long-term safety? That’s what a recent study explored, and now, Dr. Douglas Trembley is here to share the findings from the largest clinical trial safety database for a JAK inhibitor in myelofibrosis. Dr. Trembley is an Assistant Professor at the Icahn School of Medicine at Mount Sinai in New York.
